Pancreatic Cancer Research

ResearcherKindai UniversityActive in the last 2 years

Yoshifumi Takeyama

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-8034-6997; OpenAlex author ID A5102900067. Sources: OpenAlex.

Their work

Papers
20 (first author 0, last author 8)
Trials
0
Grants
0
Labs led
1
Collaborators
127
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: none · 2017: 3 papers · 2018: 1 paper · 2019: none · 2020: 1 paper · 2021: none · 2022: 1 paper · 2023: 5 papers · 2024: none · 2025: 3 papers · 2026: 5 papers

Papers 20

  1. Mortality and cancer risk in patients with chronic pancreatitis in japan: insights into the importance of surveillance for pancreatic cancer. Co-author DOI 10.1007/s00535-025-02321-0↗
  2. Conversion surgery for unresectable pancreatic ductal adenocarcinoma with liver metastasis at initial diagnosis: a nationwide multicenter study. Last author DOI 10.1007/s00535-026-02432-2↗
  3. Neoadjuvant and adjuvant treatment for pancreatic ductal adenocarcinoma in patients over 80 years old based on a nationwide clinical database. Last author DOI 10.1007/s00535-026-02480-8↗
  4. Long-term outcomes of plastic versus metal stents for preoperative biliary drainage in pancreatic cancer: a nationwide propensity score-matched analysis. Co-author DOI 10.1016/j.gie.2026.05.032↗
  5. Clinical Statistics and Outcomes of Pancreatic Neoplasms in Japan: A Retrospective Cohort Study Using the Japan Pancreatic Cancer Registry. Co-author DOI 10.1097/mpa.0000000000002694↗
  6. Clinical importance of suspicious for malignancy compared to positive for malignancy in peritoneal cytology for surgically resected pancreatic cancer. Last author DOI 10.1016/j.pan.2025.05.006↗
  7. Three Molecular Developmental Pathways of Remnant Pancreatic Cancer After Resection: A Nationwide Project Study of Japan Pancreas Society. Co-author DOI 10.1097/sla.0000000000006444↗
  8. A multicenter prospective study to determine the optimal range of lymph node dissection in pancreatic cancer surgery after neoadjuvant chemotherapy (LYMRIN-Tri… Co-author DOI 10.1371/journal.pone.0325667↗
  9. Impact of S-1 adjuvant chemotherapy longer than 6 months on survival in patients with resected pancreatic cancer: a nationwide survey by the Japan Pancreas Soc… Last author DOI 10.1002/cncr.34580↗
  10. Standard versus delayed initiation of S-1 adjuvant chemotherapy after surgery for pancreatic cancer: a secondary analysis of a nationwide cohort by the Japan P… Last author DOI 10.1007/s00535-023-01988-7↗
  11. Clinical Practice Guidelines for Pancreatic Cancer 2022 from the Japan Pancreas Society: a synopsis. Co-author DOI 10.1007/s10147-023-02317-x↗
  12. "Conversion surgery" for locally advanced pancreatic cancer: A position paper by the study group at the joint meeting of the International Association of Pancr… Last author DOI 10.1016/j.pan.2023.06.005↗
  13. Is surgical resection justified for pancreatic ductal adenocarcinoma with distant abdominal organ metastasis? A position paper by experts in pancreatic surgery… Last author DOI 10.1016/j.pan.2023.07.005↗
  14. Utility of contrast-enhanced harmonic EUS for diagnosis of portal vein invasion by pancreatic cancer. Co-author DOI 10.4103/eus-d-21-00185↗
  15. Partial Pancreatic Parenchymal Atrophy Is a New Specific Finding to Diagnose Small Pancreatic Cancer (≤10 mm) Including Carcinoma in Situ: Comparison with Loca… Co-author DOI 10.3390/diagnostics10070445↗
  16. Impact of avascular areas, as measured by contrast-enhanced harmonic EUS, on the accuracy of FNA for pancreatic adenocarcinoma. Co-author DOI 10.1016/j.gie.2017.05.052↗
  17. Association between the Risk Factors for Pancreatic Ductal Adenocarcinoma and Those for Malignant Intraductal Papillary Mucinous Neoplasm. Co-author DOI 10.1159/000481234↗
  18. A Social Program for the Early Detection of Pancreatic Cancer: The Kishiwada Katsuragi Project. Co-author DOI 10.1159/000481239↗
  19. [A Case of Conversion Surgery for a Patient with Initially Unresectable Pancreatic Cancer with a Pathological Complete Response to S-1 Chemotherapy]. Last author PMID 29394577↗
  20. Plasma concentrations of angiogenesis-related molecules in patients with pancreatic cancer. Co-author DOI 10.1093/jjco/hyr178↗

Closest collaborators

The 25 strongest of 127 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Sohei Satoi · 11 shared papers, 2023–2026 · strength 2.00
  2. Michiaki Unno · 8 shared papers, 2023–2026 · strength 1.51
  3. Atsushi Masamune · 6 shared papers, 2023–2026 · strength 1.17
  4. Tsutomu Fujii · 7 shared papers, 2023–2026 · strength 1.15
  5. Shinichi Egawa · 4 shared papers, 2025–2026 · strength 0.90
  6. Takao Itoi · 4 shared papers, 2025–2026 · strength 0.90
  7. Masamichi Mizuma · 4 shared papers, 2026 · strength 0.89
  8. Ippei Matsumoto · 8 shared papers, 2017–2026 · strength 0.84
  9. Daisuke Hashimoto · 5 shared papers, 2023–2026 · strength 0.82
  10. Yuichi Nagakawa · 5 shared papers, 2023–2025 · strength 0.75
  11. Shin Hamada · 3 shared papers, 2026 · strength 0.71
  12. Kohei Nakata · 3 shared papers, 2026 · strength 0.71
  13. Ichiro Yasuda · 3 shared papers, 2026 · strength 0.71
  14. Ken Shirabe · 3 shared papers, 2026 · strength 0.71
  15. Kazuichi Okazaki · 3 shared papers, 2025–2026 · strength 0.62
  16. Masaji Tani · 3 shared papers, 2023–2025 · strength 0.48
  17. Yuzo Kodama · 2 shared papers, 2026 · strength 0.48
  18. Yoshiki Hirooka · 3 shared papers, 2023–2026 · strength 0.47
  19. Manabu Kawai · 2 shared papers, 2026 · strength 0.47
  20. Masayuki Sho · 3 shared papers, 2023–2026 · strength 0.44
  21. Yosuke Inoue · 3 shared papers, 2023–2026 · strength 0.44
  22. Hidetoshi Eguchi · 3 shared papers, 2023–2025 · strength 0.43
  23. Masatoshi Kudo · 6 shared papers, 2012–2022 · strength 0.43
  24. Makoto Ueno · 2 shared papers, 2025 · strength 0.42
  25. Tomohisa Yamamoto · 3 shared papers, 2023–2025 · strength 0.42

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.